May 18, 2020

Use of Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19 Requiring Admission to Hospital: A Case-Population Study

Category: Article Summary

Topic: Clinical Characteristics and Health Care Setting

• Despite earlier concerns, de Abajo et al. found no evidence that RAAS inhibitors increase the risk of COVID-19 requiring admission to hospital, including fatal cases and those admitted to ICUs. The authors conducted a case-population study in Madrid, Spain including 1,139 patients and controls matched for age, sex, region, and date of admission to hospital at a ratio of 10:1. They recommend that RAAS inhibitors should not be discontinued in an attempt to prevent severe cases of COVID-19. 

de Abajo et al. (May 14, 2020). Use of Renin-Angiotensin-Aldosterone System Inhibitors and Risk of COVID-19 Requiring Admission to Hospital: A Case-Population Study. Lancet. https://doi.org/10.1016/S0140-6736(20)31030-8